Protein Engineering, Vol. 14, No. 8, 529-532,
August 2001
© 2001 Oxford University Press
COMMUNICATION |
Design of the linkers which effectively separate domains of a bifunctional fusion protein
Department of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo, Hongo, Bunkyo-ku,Tokyo 113-8656, Japan
E-mail: nagamune{at}bio.t.u-tokyo.ac.jp
| Abstract |
|---|
|
|
|---|
With the aim of separating the domains of a bifunctional fusion protein, the ability of several lengths of helix-forming peptides to separate two weakly interacting ß-can domains was compared with that of flexible linkers or of a three
-helices bundle domain. We introduced helix-forming peptide linkers A(EAAAK)nA (n = 25) between two green fluorescent protein variants, EBFP and EGFP, and investigated their spectral properties. The fluorescence resonance energy transfer from EBFP to EGFP decreased as the length of the linkers increased. The circular dichroism spectra analysis suggested that the linkers form an
-helix and the
-helical contents increased as the length of the linkers increased. The results clearly suggested the ability of the helical linkers to control the distance and reduce the interference between the domains. This `linker engineering' may open a way to the rational design of linkers which maximize the multiple functions of fusion proteins or de novo multi-domain proteins.
Keywords:
-helix/fluorescence resonance energy transfer/fusion protein/green fluorescent protein/linker engineering
| Introduction |
|---|
|
|
|---|
The gene fusion technique has become an indispensable tool in a variety of fields of biochemical research. The construction of recombinant fusion/chimeric proteins has been adopted as a means to increase the expression of soluble proteins and to facilitate protein purification. Furthermore, a wide range of applications of the gene fusion technique has been reported in the field of biotechnology. These include the immunoassays using chimeras between antibody fragments or antibody binding domains, and enzymes or green fluorescent protein variants (Maeda et al., 1996
The construction of a fusion protein involves the linking of two proteins or domains of proteins by a peptide linker. The selection of the linker sequence is particularly important for the construction of functional fusion proteins. Several studies have been made on the linker selection (Argos, 1990
; Alfthan et al., 1995
; Robinson and Sauer, 1998
; Crasto and Feng, 2000
). These studies suggested mainly that the flexibility and hydrophilicity of the linker were important not to disturb the functions of the domains. However, in our previous study on Streptococcal protein G-Vargula luciferase chimera, simple linking of the two moieties by a flexible linker did not retain the binding activity of protein G C1 domain (Maeda et al., 1997
). The loss of the binding activity of protein G could be envisaged due to some sort of interaction and interference between the two moieties. When a three
-helices bundle domain of Staphylococcal protein A (PA) was introduced between protein G and luciferase as a linker, goat/sheep IgG binding activity derived from protein G was regained. We reasoned that PA could spatially separate protein G from luciferase and thus reduce the interference between them. These results indicate that spatial separation of the hetero-functional domains of a fusion protein by proper linker peptide might be so effective that the domains work independently. However, there have been very few reports on the linkers which effectively separate the domains. Although PA was effective as a linker in our case, the length of more than 50 amino-acid residues and the additional binding activity to IgG might hinder it from general use.
In this study, we designed shorter linkers than PA to effectively separate bifunctional domains of a fusion protein. The linkers, which were expected to form a monomeric hydrophilic
-helix, were designed according to the previous study on a short peptide forming a monomeric
-helix (Marqusee and Baldwin, 1987
). In that study, the best helix-forming peptide, AEAAAKEAAAKEAAAKA [(i+4)E,K], which was stabilized by GluLys+ salt bridges, showed ~80% helicity. To our knowledge, there have been no reports that tried to introduce the helix-forming peptide to a bifunctional fusion protein as a linker, and it has been unknown whether it can actually separate the domains. To study these, we designed the linkers of different lengths A(EAAAK)nA (n = 25) based on the helix-forming peptide (i+4)E,K, and introduced them between two domains of a bifunctional fusion protein. We also introduced flexible linkers and PA into the fusion protein for the comparison.
As a model fusion protein, we employed fusion proteins of two Aequorea green fluorescent protein (GFP) variants enhanced blue fluorescent protein (EBFP; F64L, S65T, Y66H, Y145F) (Heim and Tsien, 1996
) and enhanced green fluorescent protein (EGFP; F64L, S65T) (Cormack et al., 1996
). EBFP and EGFP are useful for fluorescence resonance energy transfer (FRET) studies (Miyawaki et al., 1997
; Tsien, 1998
; Arai et al., 2000
). Because a FRET signal provides information about distances in the order of 10 to 100 Å, the technique is suitable for investigating spatial relationships of targeted molecules (Wu and Brand, 1994
; Selvin, 1995
). In this study, we examined the relative distance between EBFP and EGFP using FRET in order to evaluate designed linkers which effectively separate domains of a bifunctional fusion protein.
| Materials and methods |
|---|
|
|
|---|
Plasmid construction
For the expression of the fusion proteins, pET TRX Fusion System 32 (Novagen, Madison, WI, USA), a fusion expression system with Escherichia coli thioredoxin (Trx) was employed to enhance the solubility of the highly expressed proteins in E.coli cytoplasm (LaVallie et al., 1993
). The DNA fragment encoding EBFP was prepared from plasmid pEBFP-N1 (Clontech, Palo Alto, CA, USA) by standard PCR using Pfu DNA polymerase (Stratagene, La Jolla, CA, USA) and the primers containing the cleavage sites for EcoRV and HindIII. The amplified fragments were digested and cloned into pET32/VLEGFP (Arai et al., 2000
) between EcoRV and HindIII to give the plasmid pET32/EBFPSLEGFP. DNA sequencing was performed using the fluorescence DNA sequencer SQ-5500 (Hitachi, Tokyo, Japan). The DNA fragments encoding the designed linkers were prepared by annealing and extension using the appropriate oligo-nucleotide primers with the cleavage sites for HindIII and NotI. These were digested and cloned into pET32/EBFPSLEGFP between HindIII and NotI to give the plasmids pET32/EBFPlinkerEGFPs.
The amino acid sequences of the designed linkers were: short linker (SL), LAAA (4 aa) (derived from the cleavage sites for HindIII and NotI); flexible linker 3 (FL3), LGGGGSGGGGSGGGGSAAA (19 aa); flexible linker 4 (FL4), LSGGGGSGGGGSGGGGSGGGGSAAA (25 aa); helical linker 2 (HL2), LAEAAAKEAAAKAAA (15 aa); helical linker 3 (HL3), LAEAAAKEAAAKEAAAKAAA (20 aa); helical linker 4 (HL4), LAEAAAKEAAAKEAAAKEAAAKAAA (25 aa); helical linker 5 (HL5), LAEAAAKEAAAKEAAAKEAAAKEAAAKAAA (30 aa); B domain of Staphylococcal PA, LFNKEQQNAFYEILHLPNLNEEQRNGFIQSLKDDPS-QSANLLAEAKKLNDAQAAA (55 aa).
Protein expression and purification
Escherichia coli AD494(DE3)pLysS (Novagen) was transformed with the plasmids, and selected on LB agar plates containing 50 µg/ml ampicillin, 34 µg/ml chloramphenicol and 15 µg/ml kanamycin. For all the cultivations thereafter, LB medium containing the same concentration of the three antibiotics was used. The medium (1.5 l) was inoculated with 5 ml overnight culture at 30°C of each strain harboring pET32/EBFPlinkerEGFPs containing the designed linkers, and cultured at 30°C for 7 h. At an OD600 of
0.5, IPTG was added to a final concentration of 1 mM to induce the expression of the fusion proteins, and cells were further cultured for 12 h at 16°C. Harvested cells were resuspended in sonication buffer (50 mM sodium phosphate, 300 mM NaCl, pH 7.0) and then disrupted by freezethaws and sonication with a Sonifier 250 (Branson, Danbury, CT, USA). The supernatant was obtained after centrifugation twice at 20000 g for 20 min at 4°C. The fusion proteins which have the (His)6-tag were purified using Talon metal affinity resin (Clontech) according to the manufacturer's protocol. The fractions with sufficient fluorescence activity were collected. The proteins were specifically digested with thorombin (Novagen) between Trx and EBFP, and Trx fragments were removed by size exclusion chromatography with Superdex 75 (Amersham Pharmacia Biotech, Uppsala, Sweden). The protein concentration was determined by BCA assay kit (Pierce, Rockford, IL, USA) with bovine serum albumin as a standard.
Measurement of fluorescence intensity and circular dichroism (CD) spectra
The fluorescence intensity of the fusion proteins at 444 nm of the EBFP emission peak was measured using a fluorescence spectrophotometer F-2000 (Hitachi) with 380 nm excitation at 25°C. In order to cut the linkers between EBFP and EGFP domains, the fusion proteins (2 µM) were digested by trypsin (50 nM) at 20°C for 12 h in phosphate-buffered saline (pH 7.4). Specific digestion of the linkers was confirmed by SDSPAGE. The CD spectra of the fusion proteins were measured using a CD spectropolarimeter J-725 (Jasco, Tokyo, Japan) at 25°C.
| Results and discussion |
|---|
|
|
|---|
Sufficient amounts of the fusion proteins having each linker were expressed and purified, with yields of 1020 mg per 1.5 l culture. All of the fusion proteins retained sufficient fluorescence derived from both EBFP and EGFP (not shown). To estimate the FRET efficiency from EBFP to EGFP, the linkers between the two were digested by trypsin under the condition where both EBFP and EGFP domains remained intact, which was confirmed by SDSPAGE (not shown). Based on this negative control where the fluorescence intensity of EBFP (donor) without FRET could be evaluated, FRET efficiency (ET) was calculated from the ratio of EBFP fluorescence intensities before and after trypsin digestion (Table I
|
The result of 10% polyacrylamide gel electrophoresis of fusion proteins in native conditions (native-PAGE) is shown in Figure 1
|
Figure 2A
-helical contents estimated by Bolotina's method (Bolotina et al., 1980
-helices with two minima at ~222 nm (n
* transition) and ~208 nm (
transition). The results indicate that these linkers (HL3, HL4, HL5 and PA) form an
-helical structure in the fusion proteins. Considering the differential values of the mean residue ellipticity at 222 nm (
[
]222), which is an index of
-helical contents, the
-helical contents of the helical linkers (HL2, HL3, HL4 and HL5) increased in proportion to the number of linker residues. On the other hand, the
[
]222 of EBFPFL3-EGFP and EBFPFL4-EGFP were higher than the others. This was probably because the flexible linkers formed a random coiled conformation.
|
These results indicate that the helical linkers can effectively separate the domains of fusion proteins and the distance between the domains can be controlled by changing the repetitions of the EAAAK motif. According to the FRET measurements, the HL4 linker can equally work well as a PA linker. We think that HL4 and HL5 linkers are advisable candidates for the linker of bifunctional fusion proteins, because they can effectively separate the functional domains and avoid inadequate interaction between the domains. To our knowledge, this is the first comprehensive report of helical linkers with the aim of separating the domains of bifunctional fusion proteins and also controlling the spatial distance between them.
The design of linkers is more important if a multi-domain protein is designed de novo. The control of the distance and the orientation of the domains in order to maximize the desired functions is a demanding task in near-future protein engineering. Here we would like to propose a term `linker engineering', whose objective is the rational control of the linker conformation, flexibility and the distance between protein domains to create a multi-functional fusion protein. This study suggests the potential of the helical linkers as first candidates for its building block.
| Notes |
|---|
1 To whom correspondence should be addressed. E-mail: nagamune{at}bio.t.u-tokyo.ac.jp
| Acknowledgments |
|---|
We thank S. Yamaguchi, N. Shigi, T. Suzuki and K. Watanabe at the University of Tokyo for their help with CD measurements. R.A. was supported by Research Fellowships of the Japan Society for the Promotion of Science for Young Scientists. This study was also supported in part by a Grant-in-Aid for Scientific Research on Priority Areas (No. 296-10145107) and for Scientific Research (B09450301) from the Ministry of Education, Science, Sports and Culture of Japan, and funded in part by Biodesign Research Promotion Group of the Institute of Physical and Chemical Research (RIKEN), Japan.
| References |
|---|
|
|
|---|
Alfthan,K., Takkinen,K., Sizmann,D., Soderlund,H. and Teeri,T.T. (1995) Protein Eng., 8, 725731.
Arai,R., Ueda,H. and Nagamune,T. (1998) J. Ferment. Bioeng., 86, 440445.
Arai,R., Ueda,H., Tsumoto,K., Mahoney,W.C., Kumagai,I. and Nagamune,T. (2000) Protein Eng., 13, 369376.
Argos,P. (1990) J. Mol. Biol., 211, 943958.[Web of Science][Medline]
Bird,R.E., Hardman,K.D., Jacobson,J.W., Johnson,S., Kaufman,B.M., Lee,S.M., Lee,T., Pope,S.H., Riordan,G.S. and Whitlow,M. (1988) Science, 242, 423426.
Bolotina,I.A., Chekhov,V.O., Lugauskas,V. and Ptitsyn,O.B. (1980) Mol. Biol. (USSR), 14, 902909.
Bulow,L. (1987) Eur. J. Biochem., 163, 443448.[Web of Science][Medline]
Cormack,B.P., Valdivia,R. and Falkow,S. (1996) Gene, 173, 3338.[Web of Science][Medline]
Crasto,J.C. and Feng,J. (2000) Protein Eng., 13, 309312.
Deléage,G. and Geourjon,C. (1993) Comput. Appl. Biosci., 9, 197199.
Heim,R. and Tsien,R.Y. (1996) Curr. Biol., 6, 178182.[Web of Science][Medline]
LaVallie,E.R., DiBlasio,E.A., Kovacic,S., Grant,K.L., Schendel,P.F. and McCoy,J.M. (1993) Biotechnology, 11, 187193.[Medline]
Ljungcrantz,P., Carlsson,H., Mansson,M.O., Buckel,P., Mosbach,K. and Bulow,L. (1989) Biochemistry, 28, 87868792.[Medline]
Maeda,Y., Ueda,H., Hara,T., Kazami,J., Kawano,G., Suzuki,E. and Nagamune,T. (1996) Biotechniques, 20, 116121.[Web of Science][Medline]
Maeda,Y., Ueda,H., Kazami,J., Kawano,G., Suzuki,E. and Nagamune,T. (1997) Anal. Biochem., 249, 147152.[Web of Science][Medline]
Marqusee,S. and Baldwin,R.L. (1987) Proc. Natl Acad. Sci. USA, 84, 88988902.
Miyawaki,A., Llopis,J., Heim,R., McCaffery,J.M., Adams,J.A., Ikura,M. and Tsien,R.Y. (1997) Nature, 388, 882887.[Medline]
Morii,H., Uedaira,H., Ogata,K., Ishii,S. and Sarai,A. (1999) J. Mol. Biol., 292, 909920.[Web of Science][Medline]
Ormö,M., Cubitt,A.B., Kallio,K., Gross,L.A., Tsien,R.Y. and Remington,S.J. (1996) Science, 273, 13921395.[Abstract]
Phillips,G.N.,Jr (1997) Curr. Opin. Struct. Biol., 7, 821827.[Web of Science][Medline]
Robinson,C.R. and Sauer,R.T. (1998) Proc. Natl Acad. Sci. USA, 95, 59295934.
Selvin,P.R. (1995) Methods Enzymol., 246, 300334.[Web of Science][Medline]
Suzuki,C., Ueda,H., Tsumoto,K., Mahoney,W.C., Kumagai,I. and Nagamune,T. (1999) J. Immunol. Methods, 224, 171184.[Web of Science][Medline]
Tsien,R.Y. (1998) Annu. Rev. Biochem., 67, 509544.[Web of Science][Medline]
Wu,P. and Brand,L. (1994) Anal. Biochem., 218, 113.[Web of Science][Medline]
Yang,F., Moss,L.G. and Phillips,G.N.,Jr (1996) Nature Biotechnol., 14, 12461251.[Web of Science][Medline]
Received February 20, 2001; accepted May 14, 2001.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
T. S. Cardno, E. S. Poole, S. F. Mathew, R. Graves, and W. P. Tate A homogeneous cell-based bicistronic fluorescence assay for high-throughput identification of drugs that perturb viral gene recoding and read-through of nonsense stop codons RNA, August 1, 2009; 15(8): 1614 - 1621. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Afshar, T. Asai, and S. L. Morrison Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer Mol. Cancer Ther., January 1, 2009; 8(1): 185 - 193. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. A. Kaserer, X. Jiang, Q. Xiao, D. C. Scott, M. Bauler, D. Copeland, S. M. C. Newton, and P. E. Klebba Insight from TonB Hybrid Proteins into the Mechanism of Iron Transport through the Outer Membrane J. Bacteriol., June 1, 2008; 190(11): 4001 - 4016. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Balannik, R. A. Lamb, and L. H. Pinto The Oligomeric State of the Active BM2 Ion Channel Protein of Influenza B Virus J. Biol. Chem., February 22, 2008; 283(8): 4895 - 4904. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. L. Kolossov, B. Q. Spring, A. Sokolowski, J. E. Conour, R. M. Clegg, P. J. A. Kenis, and H. R. Gaskins Engineering Redox-Sensitive Linkers for Genetically Encoded FRET-Based Biosensors Experimental Biology and Medicine, February 1, 2008; 233(2): 238 - 248. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Horisawa, S. Tateyama, M. Ishizaka, N. Matsumura, H. Takashima, E. Miyamoto-Sato, N. Doi, and H. Yanagawa In vitro selection of Jun-associated proteins using mRNA display Nucleic Acids Res., December 2, 2004; 32(21): e169 - e169. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yonezawa, N. Doi, T. Higashinakagawa, and H. Yanagawa DNA Display of Biologically Active Proteins for In Vitro Protein Selection J. Biochem., March 1, 2004; 135(3): 285 - 288. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Jullien, F. Sampieri, A. Enjalbert, and J.-P. Herman Regulation of Cre recombinase by ligand-induced complementation of inactive fragments Nucleic Acids Res., November 1, 2003; 31(21): e131 - e131. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||








